Last reviewed · How we verify
CGT003 (E2F Duplex Decoy)
CGT003 is a decoy oligonucleotide that binds and sequesters E2F transcription factors, blocking their ability to drive cell proliferation and survival.
CGT003 is a decoy oligonucleotide that binds and sequesters E2F transcription factors, blocking their ability to drive cell proliferation and survival. Used for Solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | CGT003 (E2F Duplex Decoy) |
|---|---|
| Sponsor | Anesiva, Inc. |
| Drug class | Decoy oligonucleotide |
| Target | E2F transcription factors |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
E2F transcription factors are key regulators of the cell cycle and are often dysregulated in cancer and fibrotic diseases. By acting as a molecular decoy, CGT003 competitively binds E2F proteins and prevents them from activating their target genes, thereby inhibiting aberrant cell proliferation. This mechanism is intended to reduce pathological cell growth in conditions driven by E2F overactivity.
Approved indications
- Solid tumors (specific indication under investigation in phase 3)
Common side effects
Key clinical trials
- Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures (PHASE3)
- Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CGT003 (E2F Duplex Decoy) CI brief — competitive landscape report
- CGT003 (E2F Duplex Decoy) updates RSS · CI watch RSS
- Anesiva, Inc. portfolio CI